Total amount raised
$459.7 Millions
Latest funding date
02/01/2022
Location
Synthego has successfully raised funds through multiple rounds, with the latest being a Series E that closed on February 17, 2022. The company is backed by 29 investors, including AAF Management Ltd. and RA Capital Management.
Keep reading to explore the intricacies of Synthego's fundraising journey and the investors backing this innovative platform.
What Is Synthego?
Synthego, founded on July 1, 2012, is a genome engineering company based in Redwood City, California. The company was established by Alex Pesch, Michael Dabrowski, and Paul Dabrowski.
Operating in industries such as biotechnology, genetics, and life sciences, Synthego leverages CRISPR technology to accelerate life science research and development. The company employs between 101-250 people.
How Much Funding Has Synthego Raised?
- Seed Round
- Amount Raised: Not publicly disclosed
- Date: August 14, 2012
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's operations and initial research in genome engineering.
- Debt Financing
- Amount Raised: $250K
- Date: August 14, 2012
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To secure additional capital for early-stage development and operational costs.
- Series A
- Amount Raised: $8.3M
- Date: July 5, 2013
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand research capabilities and develop initial product offerings.
- Venture Round
- Amount Raised: CN¥1M
- Date: August 19, 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop and refine CRISPR technology applications.
- Series B
- Amount Raised: $41M
- Date: January 4, 2017
- Lead Investors: 8VC
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and enhance product development.
- Corporate Round
- Amount Raised: Not publicly disclosed
- Date: October 19, 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To form strategic partnerships and collaborations.
- Series C
- Amount Raised: $110M
- Date: October 23, 2018
- Lead Investors: Founders Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the development of CRISPR-based technologies and expand market reach.
- Series D
- Amount Raised: $100M
- Date: August 26, 2020
- Lead Investors: 8VC, RA Capital Management, Wellington Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance CRISPR technology and support therapeutic development.
- Series E
- Amount Raised: $200M
- Date: February 17, 2022
- Lead Investors: Perceptive Advisors
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the creation of a cell and gene therapy discovery and development ecosystem.
Synthego has raised a total of $660.55M. The current valuation is Not publicly disclosed.
Key Investors
- Perceptive Advisors
- Details: Perceptive Advisors is a leading investment firm focused on the healthcare sector. They have a strong track record in biotechnology and pharmaceuticals.
- Investment Focus Areas: Life sciences, biotechnology, healthcare
- Notable Investments: Freenome
- SoftBank Vision Fund 2
- Details: SoftBank Vision Fund 2 is a global investment fund that focuses on technology-driven companies. They are known for their significant investments in AI and robotics.
- Investment Focus Areas: Technology, artificial intelligence, robotics
- Notable Investments: Multiple high-profile tech companies
- RA Capital Management
- Details: RA Capital Management is a life sciences-focused investment firm. They specialize in healthcare and biotechnology investments.
- Investment Focus Areas: Life sciences, healthcare
- Notable Investments: Not publicly disclosed
- Wellington Management
- Details: Wellington Management is a global investment management firm. They manage a broad range of asset classes including equities and fixed income.
- Investment Focus Areas: Global investment management
- Notable Investments: Not publicly disclosed
- Moore Strategic Ventures
- Details: Moore Strategic Ventures is the private investment arm of Louis Bacon. They invest across various sectors including technology and healthcare.
- Investment Focus Areas: Technology, healthcare, financial services
- Notable Investments: Various strategic investments
What's Next for Synthego?
Synthego stands at the cusp of a transformative era in genome engineering. With a recent $200 million infusion, the company is poised to accelerate the development of a cell and gene therapy ecosystem. This funding will bolster their Halo and Eclipse Platforms and support next-generation technologies like CRISPROff, positioning Synthego to lead in the rapidly evolving biotech landscape.
Future fundraising opportunities seem promising, given the strong backing from high-profile investors. As Synthego scales its operations and technology, additional rounds of funding could further enhance its market position. However, the company must navigate regulatory challenges and maintain high standards of quality and efficacy to stay ahead in the competitive field of genome engineering.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Synthego and gather other critical business insights. Sign up for free to enhance your sales strategies and stay ahead in the competitive market.
